Pervasis Therapeutics announced the presentation of interim data from its Phase 1/2 study of PVS-10200 to prevent restenosis in patients with peripheral arterial disease (PAD) who undergo an angioplasty and stent procedure in the superficial femoral artery. This trial was an open-label dose escalation study designed to evaluate the safety, feasibility and impact of PVS-10200 on the incidence of major adverse events. Secondary endpoints include the rates of target lesion revascularization, primary patency and restenosis. Initial findings from the study were said to show a low rate and nature of adverse events associated with PVS-10200 as a treatment option for vascular injury. 

PVS-10200 is a biologically active therapy developed using tissue-engineered allogeneic endothelial cells, and is designed to reestablish healthy vasculature following common interventions to treat PAD and potentially other conditions.

For more information call (617) 621-3407 or visit www.pervasistx.com